CDXS Codexis

Codexis to Hold 2019 Fourth Quarter and Full Year Conference Call on February 27

Codexis to Hold 2019 Fourth Quarter and Full Year Conference Call on February 27

REDWOOD CITY, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report 2019 fourth quarter and full year financial results after market close on Thursday, February 27, 2020. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss financial results and provide a company update.

Live Call:U.S.855 890 8665
 International720 634 2938
 Passcode8768898
   
Live Webcast: 
 The webcast will be archived for 90 days.
   
Replay:U.S.855 859 2056
 International404 537 3406
 Passcode8768898
 The replay will be available for 48 hours
  

About Codexis, Inc.

Codexis is a leading protein engineering company that applies its proprietary CodeEvolver® technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis’ proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes. For more information, see .

Contact:

LHA Investor Relations

Jody Cain, 310 691 7100

EN
20/02/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Codexis

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: December 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Codexis Announces Signing of Lease for GMP Manufacturing Facility

Codexis Announces Signing of Lease for GMP Manufacturing Facility REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it has signed a lease for a 34,000 square foot GMP manufacturing facility in Hayward, California. The multi-purpose facility will allow Codexis to expand its internal capabilities into GMP manufacturing of siRNA and other oligonucleotides using its ECO Synthesis platform. The company expects to begin modific...

 PRESS RELEASE

Codexis Reports Third Quarter 2025 Financial Results

Codexis Reports Third Quarter 2025 Financial Results Announces signing of $37.8m Supply Assurance Agreement with Merck Organizational changes streamline company and reduce operational expenses Cash runway extended through 2027 REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced financial results for the third quarter ended September 30, 2025. The company also provided a business update that includes signing a $37.8m Supply Ass...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch